Neuropeptide Y (NPY): a vasoconstrictor in the eye, brain and other tissues in the rabbit.
The effect of neuropeptide Y (NPY) on uveal vascular resistance was studied in rabbits by direct determination of uveal blood flow from a cannulated vortex vein. Regional blood flows, in the eye, the brain and several other tissues, were measured, with radioactive microspheres, during neuropeptide Y-infusion in rabbits with and without alpha-adrenoceptor blockade. Intravenous infusion of increasing doses of neuropeptide Y caused a dose-dependent increase in the total uveal vascular resistance. Maximal effect, a 70% increase, was achieved with 120 pmol kg-1 min-1. In the microsphere experiments, this dose rate was given i.v. over 10 minutes and blood flow determinations were made before and at 2 and 10 minutes after the start of the infusion. After 2 minutes of neuropeptide Y, there were marked blood flow reductions in the spleen, kidneys, adrenal glands, gastro-intestinal tract, choroid plexus and pineal and pituitary gland. The effect in the eye was small at 2 minutes, but at 10 minutes local blood flows in the choroid and the ciliary body were decreased by 50% and the iridal blood flow by 30%. Retinal blood flow was not affected by neuropeptide Y. At 10 minutes there were also significant blood flow reductions in the brain, tongue, masseter muscle and several glandular tissues. The effects of neuropeptide Y on local blood flow in rabbits that had been subjected to alpha-adrenoceptor blockade were very similar to the effects in the animals without alpha-adrenoceptor blockade. The results show that, in the rabbit, neuropeptide Y has marked effects on local blood flows in several tissues, including the eye, and suggest that neuropeptide Y may significantly contribute to the uveal vasoconstriction during sympathetic nerve stimulation.
Department of Physiology and Medical Biophysics, University of Uppsala, Sweden.
S F
SF
Nilsson
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D005123:Eye / Q000098:blood supply*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D008863:Microspheres; D009478:Neuropeptide Y / Q000494:pharmacology*; D011817:Rabbits; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology; D014602:Uvea / Q000098:blood supply; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents
D000317:Adrenergic alpha-Antagonists; D009478:Neuropeptide Y; D014662:Vasoconstrictor Agents